Rapport Therapeutics (RAPP) Other financing activities (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Other financing activities data on record, last reported at $273000.0 in Q1 2026.
- On a quarterly basis, Other financing activities changed N/A to $273000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $15.8 million, a 1.79% increase, with the full-year FY2023 number at $134000.0, changed N/A from a year prior.
- Other financing activities reached $273000.0 in Q1 2026 per RAPP's latest filing, up from $63000.0 in the prior quarter.
- Over the last five years, Other financing activities for RAPP hit a ceiling of $15.5 million in Q2 2024 and a floor of -$29000.0 in Q2 2023.
- A 4-year average of $3.2 million and a median of $87000.0 in 2024 define the central range for Other financing activities.
- Peak YoY movement for Other financing activities: soared 53548.28% in 2024, then tumbled 99.59% in 2025.
- Tracing RAPP's Other financing activities over 4 years: stood at -$29000.0 in 2023, then skyrocketed by 53548.28% to $15.5 million in 2024, then crashed by 99.59% to $63000.0 in 2025, then soared by 333.33% to $273000.0 in 2026.
- Business Quant data shows Other financing activities for RAPP at $273000.0 in Q1 2026, $63000.0 in Q2 2025, and $15.5 million in Q2 2024.